Sun S, Weil M H, Tang W, Fukui M
Institute of Critical Care Medicine, Palm Springs, CA 92262-5309, USA.
Crit Care Med. 1996 Dec;24(12):2035-41. doi: 10.1097/00003246-199612000-00017.
Earlier studies demonstrated that hypertonic buffer agents administered during cardiopulmonary resuscitation (CPR) altered neither myocardial pH nor cardiac resuscitability. The rationale for the routine use of buffer agents for CPR has therefore been challenged. However, when these buffer agents are administered during CPR, they may have favorable effects on the postresuscitation course. Postresuscitation myocardial dysfunction has more recently emerged as a potentially fatal complication after successful cardiac resuscitation. Options for prevention and management of this complication have prompted the present studies, in which the effects of buffer agents administered during CPR are evaluated as to their effects on postresuscitation myocardial function and survival.
Prospective, randomized, controlled animal study.
University animal laboratory.
Forty male Sprague-Dawley rats (450 to 570 g).
Ventricular fibrillation was induced electrically. Mechanical Ventilation and percordial compression were initiated after either a 4- or an 8-min interval of untreated cardiac arrest. Sodium bicarbonate as a CO2-generating buffer, Carbicarb and tromethamine as CO2-consuming buffers, or hypertonic saline placebo were injected as a bolus into the right atrium during CPR. Defibrillation after 10 mins of cardiac arrest and CPR was successful in each instance. No differences in the electric power required for successful resuscitation were documented. Left ventricular pressure, rate of left ventricular pressure increase measured at a left ventricular pressure of 40 mm Hg (dP/dt40), rate of left ventricular pressure decline (-dP/dt), and end-tidal PCO2 were continuously measured for 240 mins after successful resuscitation.
Decreases in coronary perfusion pressure were observed after each buffer or placebo injection. As anticipated, end-tidal PCO2 increased after bicarbonate and decreased after Carbicarb or tromethamine. Postresuscitation left ventricular function was significantly decreased in all animals. However, there was significantly less depression in rate of left ventricular pressure increase measured at a left ventricular pressure of 40 mm Hg (dP/dt40), rate of left ventricular pressure decline (-dP/dt), and a lower left ventricular diastolic pressure with both Carbicarb and tromethamine in association with significant increases in postresuscitation survival rate. When the duration of untreated cardiac arrest was increased to 8 mins, the severity of postresuscitation left ventricular dysfunction was magnified and postresuscitation myocardial function and survival were significantly improved with both CO2-generating and CO2-consuming buffer agents.
Although buffer agents may not improve the success of resuscitation when administered during CPR, they may ameliorate postresuscitation myocardial dysfunction and thereby improve postresuscitation survival.
早期研究表明,在心肺复苏(CPR)期间给予高渗缓冲剂既不会改变心肌pH值,也不会改变心脏复苏能力。因此,CPR常规使用缓冲剂的基本原理受到了挑战。然而,当这些缓冲剂在CPR期间给予时,它们可能对复苏后病程产生有利影响。复苏后心肌功能障碍最近已成为心脏复苏成功后一种潜在的致命并发症。针对该并发症的预防和管理方法促使了本研究,其中评估了CPR期间给予缓冲剂对复苏后心肌功能和生存的影响。
前瞻性、随机、对照动物研究。
大学动物实验室。
40只雄性Sprague-Dawley大鼠(450至570克)。
通过电诱导心室颤动。在未经处理的心脏骤停4或8分钟间隔后开始机械通气和胸外按压。在CPR期间,将作为产生CO2的缓冲剂的碳酸氢钠、作为消耗CO2的缓冲剂的卡比多巴和氨丁三醇或高渗盐水安慰剂作为推注剂注入右心房。在心脏骤停和CPR 10分钟后进行除颤,每次均成功。记录成功复苏所需的电功率无差异。在成功复苏后连续240分钟测量左心室压力、在左心室压力为40 mmHg时测量的左心室压力上升速率(dP/dt40)、左心室压力下降速率(-dP/dt)和呼气末PCO2。
每次注射缓冲剂或安慰剂后均观察到冠状动脉灌注压力降低。如预期的那样,碳酸氢钠注射后呼气末PCO2升高,卡比多巴或氨丁三醇注射后呼气末PCO2降低。所有动物复苏后的左心室功能均显著降低。然而,卡比多巴和氨丁三醇组在左心室压力为40 mmHg时测量的左心室压力上升速率(dP/dt40)、左心室压力下降速率(-dP/dt)的降低明显较少,左心室舒张压较低,且复苏后存活率显著提高。当未经处理的心脏骤停持续时间增加到8分钟时,复苏后左心室功能障碍的严重程度加剧,产生CO2和消耗CO2的缓冲剂均显著改善了复苏后心肌功能和存活率。
尽管缓冲剂在CPR期间给予时可能不会提高复苏成功率,但它们可能改善复苏后心肌功能障碍,从而提高复苏后存活率。